Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Syros Pharmaceuticals (NASDAQ:SYRS) posted sales of $7.80 million. Earnings were up 8.51%, but Syros Pharmaceuticals still reported an overall loss of $23.81 million. In Q3, Syros Pharmaceuticals brought in $5.70 million in sales but lost $26.03 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.